Mutations in the STAT1‑interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy

Anjum,Sadia; Afzal,Muhammad   Sohail; Ahmad,Tahir; Aslam,Baber; Waheed,Yasir; Shafi,Talha; Qadri,Ishtiaq

doi:10.3892/mmr.2013.1541

Mutations in the STAT1‑interacting domain of the hepatitis C virus core protein modulate the response to antiviral therapy

Authors:
- Sadia Anjum
- Muhammad Sohail Afzal
- Tahir Ahmad
- Baber Aslam
- Yasir Waheed
- Talha Shafi
- Ishtiaq Qadri
View Affiliations

Affiliations: Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad 44000, Pakistan
Published online on: June 25, 2013 https://doi.org/10.3892/mmr.2013.1541
Pages: 487-492

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RNA viruses, such as hepatitis C virus (HCV), have markedly error-prone replication, resulting in high rates of mutagenesis. In addition, the standard treatment includes ribavirin, a base analog that is likely to cause mutations in different regions of the HCV genome, resulting in deleterious effects on HCV itself. The N-terminal region of the core protein is reported to block interferon (IFN) signaling by interaction with the STAT1‑SH2 domain, resulting in HCV resistance to IFN therapy. In this study, mutations in the HCV core protein from IFN/ribavirin‑treated patients were analyzed, with particular focus on the N‑terminal domain of the HCV core which is reported to interact with STAT1. HCV PCR positive patients enrolled in this study were either undergoing pegylated IFN/ribavirin bitherapy and had completed 12 weeks of initial treatment or were treatment‑naïve patients. The HCV core protein was cloned and sequenced from these patients and mutations observed in the STAT1‑interacting domain of the core protein from treated patients were characterized using in silico interaction to depict the role of these mutations in disease outcomes. Our results suggest that the amino acids at positions 2, 3, 8, 16 and 23 of the HCV core protein are critical for core-STAT1 interaction and ribavirin-induced mutations at these positions interfere with the interaction, resulting in a better response of the treated patients. In conclusion, this study anticipates that HCV core residues 2, 3, 8, 16 and 23 directly interact with STAT1. We propose that IFN/ribavirin bitherapy‑induced mutations in the STAT1‑interacting domain of the HCV core protein may be responsible for the improved therapeutic response and viral clearance, thus amino acids 1-23 of the N-terminus of the core protein are an ideal antiviral target. However, this treatment may give rise to resistant variants that are able to escape the current therapy. We propose similar studies in responsive and non-responsive genotypes in order to gain a broader picture of this proposed mechanism of viral clearance.

View Figures

View References

1	Alter MJ, Mast EE, Moyer LA and Margolis HS: Hepatitis C. Infect Dis Clin North Am. 12:13–26. 1998. View Article : Google Scholar
2	Chen SL and Morgan TR: The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 3:47–52. 1997.
3	Lin W, Kim SS, Yeung E, Kamegaya Y, Blackard JT, Kim KA, Holtzman MJ and Chung RT: Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol. 80:9226–9235. 2006. View Article : Google Scholar : PubMed/NCBI
4	Melén K, Fagerlund R, Nyqvist M, Keskinen P and Julkunen I: Expression of hepatitis C virus core protein inhibits interferon-induced nuclear import of STATs. J Med Virol. 73:536–547. 2004.PubMed/NCBI
5	de Lucas S, Bartolome J and Carreno V: Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Infect Dis. 191:93–99. 2005.PubMed/NCBI
6	Hadziyannis S, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A and Ackrill AM; PEGASYS International Study Group. Peginterferon-α2a and ribavirin therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Annal Intern Med. 140:346–355. 2004.
7	Dore GJ, Matthews GV and Rockstroh J: Future of hepatitis C therapy: development of direct-acting antivirals. Curr Opin HIV AIDS. 6:508–513. 2011. View Article : Google Scholar : PubMed/NCBI
8	Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H, Kitamura T and Miyake S: Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol. 43:623–629. 2005. View Article : Google Scholar : PubMed/NCBI
9	Chung RT, Gale M Jr, Polyak SJ, Lemon SM, Liang TJ and Hoofnagle JH: Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology. 47:306–320. 2008. View Article : Google Scholar : PubMed/NCBI
10	Herrmann E, Lee JH, Marinos G, Modi M and Zeuzem S: Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology. 37:1351–1358. 2003. View Article : Google Scholar : PubMed/NCBI
11	Ohno T, Mizokami M, Wu RR, Saleh MG, Ohba KI, Orito E, Mukaide M, Williams R and Lau JY: New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 35:201–207. 1997.PubMed/NCBI
12	Waheed Y, Tahir S, Ahmad T and Qadri I: Sequence comparison and phylogenetic analysis of core gene of hepatitis C virus from Pakistani population. Afr J Biotechnol. 9:4561–4567. 2010.
13	Wu S, Skolnick J and Zhang Y: Ab initio modeling of small proteins by iterative TASSER simulations. BMC Biol. 5:172007. View Article : Google Scholar : PubMed/NCBI
14	de Vries SJ, van Dijk M and Bonvin AM: The HADDOCK web server for data-driven biomolecular docking. Nat Protoc. 5:883–897. 2010.PubMed/NCBI
15	Prevelige PE Jr: Inhibiting virus-capsid assembly by altering the polymerisation pathway. Trends Biotechnol. 16:61–65. 1998. View Article : Google Scholar : PubMed/NCBI
16	Klein KC, Dellos SR and Lingappa JR: Identification of residues in the hepatitis C virus core protein that are critical for capsid assembly in a cell-free system. J Virol. 79:6814–6826. 2005. View Article : Google Scholar : PubMed/NCBI
17	Tang X, Wagoner J, Negash A, Austin M, McLauchlan J, Hahn YS, Rosen HR and Polyak SJ: Functional characterization of core genes from patients with acute hepatitis C. J Infect Dis. 201:912–922. 2010. View Article : Google Scholar : PubMed/NCBI
18	Hourioux C, Ait-Goughoulte M, Patient R, Fouquenet D, Arcanger-Doudet F, Brand D, Martin A and Roingeard P: Core protein domains involved in hepatitis C virus-like particle assembly and budding at the endoplasmic reticulum membrane. Cell Microbiol. 9:1014–1027. 2007. View Article : Google Scholar : PubMed/NCBI
19	Lin W, Choe WH, Hiasa Y, Kamegaya Y, Blackard JT, Schmidt EV and Chung RT: Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology. 128:1034–1041. 2005. View Article : Google Scholar : PubMed/NCBI
20	Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, Matsuda M, Kobayashi M, Arase Y, Ikeda K and Kumada H: Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology. 48:372–380. 2005. View Article : Google Scholar
21	Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Nakamura Y and Kumada H: Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 52:421–429. 2010. View Article : Google Scholar : PubMed/NCBI
22	Hofmann WP, Polta A, Herrmann E, Mihm U, Kronenberger B, Sonntag T, Lohmann V, Schönberger B, Zeuzem S and Sarrazin C: Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology. 132:921–930. 2007. View Article : Google Scholar : PubMed/NCBI